Original Article
Diabetes, COVID 19 and mucormycosis: Clinical spectrum and outcome in a tertiary care medical center in Western India

https://doi.org/10.1016/j.dsx.2021.102196Get rights and content

Highlights

  • There has been recent surge in cases of Mucormycosis during COVID-19 pandemic.

  • The Incidence of COVID Associated Mucormycois (CAM) was 3.36% in hospitalized cases of COVID-19.

  • Diabetes mellitus was the most frequent co-morbidity in patients with CAM in (87.5%) cases.

  • Majority of cases (65.6%) of CAM were in Post Covid Syndrome.

Abstract

Aims

Diabetes Mellitus predisposes patients to invasive fungal infections. There has been a recent surge of Mucormycosis with COVID 19 infection particularly in patients with diabetes. This study aims to study the clinical spectrum of CAM (COVID -associated Mucormycosis) with diabetes and subsequent outcomes.

Material and methods

This was a descriptive study conducted at a single COVID Care Centre in India in patients with COVID Associated Mucormycosis from April 12, 2021 to May 31, 2021.

Results

Among 953 hospitalized patients with COVID 19 infection, 32 patients had CAM with an incidence of 3.36%. In patients with CAM, 87.5% had Diabetes Mellitus as the most common co-morbidity. The majority of the patients had poor glycemic control with a mean HbA1c of 9.06%. Out of the total study population, 93% had prior exposure to high dose corticosteroids. During the study period, 12.5% patients of CAM did not survive.

Conclusion

Mucormycosis is an angioinvasive fungal infection with high mortality. The disease has surged in COVID 19 pandemic due to uncontrolled diabetes and improper corticosteroid use.

Keywords

Mucormycosis
Diabetes
COVID-19

Cited by (0)

View Abstract